Cover Image
市場調查報告書

PharmaPoint:老年癡呆症 - 全球醫藥品市場至2023年的預測與市場分析

PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2026

出版商 GlobalData 商品編碼 296448
出版日期 內容資訊 英文 330 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:老年癡呆症 - 全球醫藥品市場至2023年的預測與市場分析 PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2026
出版日期: 2017年09月15日 內容資訊: 英文 330 Pages
簡介

老年癡呆症 (AD) ,是有憶力衰退、認知障礙、功能降低特徵的進行性的神經退化性疾病記。

本報告提供全球AD治療藥市場相關調查分析、疾病的概要與指南、競爭情形、主要藥物的詳細資訊 (產品說明、安全性、有效性) 、SWOT分析、銷售額預測、影響分析 (趨勢、推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
  • 病期分類系統
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
    • AD的家族病史,增加AD的風險7.5倍
    • ApoE ε4 對立遺傳基因,增加AD的風險3倍
    • 心血管疾病的危險因素,使AD的風險倍增
    • 65歲以上,AD的發病數量和患病人數每5歲倍增
    • 糖尿病使男性的AD風險倍增,不過使女性的AD風險微增
    • 女性AD發病的風險,有比男性高1.5倍的趨勢
    • 憂鬱症增加AD的風險3倍,是最常見的共生病症
    • AD患者的70%左右也患不安神經症
    • 精神病性激越 (興奮) ,是AD患者的一般共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
    • 中國
    • 印度
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 流行病學預測
  • 議論

第5章 疾病的管理

  • 診斷概要
  • 治療概要
  • 臨床診療
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度

第6章 競爭評估

  • 概要
  • 產品簡介:領導品牌
  • 其他藥劑/藥效分類

第7章 未滿足需求和機會

  • 有緩解疾病性的作用機制的藥物
  • 前驅期或發病前階段的診斷
  • 症狀控制的改善
  • 治療容易度

第8章 開發平台評估

  • 概要
  • 臨床試驗製圖
  • 臨床開發中的潛力藥物

第9章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Actavis
    • Lundbeck
    • Eisai
    • Pfizer
    • Novartis
    • Roche
    • Eli Lilly
    • Merck & Co. 280
    • AstraZeneca
    • 武田藥品工業

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC149PIDR

Alzheimer's disease (AD) is a looming endangerment to global health, and a threat to the world economy. One in every three seniors in the US dies with AD or another form of dementia. It is the sixth leading overall cause of death in the US, and ranks as the fifth leading cause of death among those aged 65 years old or older. The overall costs of AD were estimated to reach upwards of $259B in 2017 in the US alone, $175B (68%) of which was paid for by Medicaid or Medicare. The government spending on AD is expected to rise sharply across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) due to the aging global population.

During 2016-2026, the growth of the AD market will be driven by the entry of disease-modifying therapies (DMTs), including the passive immunotherapies aducanumab, gantenerumab, and crenezumab, which will have significant uptake in the US, the 5EU (France, Germany, Italy, Spain, and UK), and Japan. In addition to DMTs, novel symptomatic therapies with innovative mechanisms of action are anticipated to become routinely used in care over the 10-year forecast period.

The major drivers of growth in the AD market in the 7MM over the forecast period include -

  • Entry of DMTs, including the passive immunotherapies aducanumab, gantenerumab, and crenezumab, and the beta-secretase (BACE) inhibitors verubecestat and lanabecestat.
  • Entry of novel symptomatic therapies such as intepirdine.
  • Entry of DMTs targeting presymptomatic AD population: CAD106, CNP520, and JNJ-54861911.
  • Rising prevalence of AD and MCI.
  • Expanding diagnostic capability.
  • Growing social awareness of the disease.

In 2016, it is estimated that the global AD market had reached around $2.9B across the 7MM. By the end of the forecast period in 2026, sales across these markets will reach about $14.8B, increasing at a Compound Annual Growth Rate (CAGR) of 17.5% over the 10-year forecast period, which will see the launch of 20 new therapies, including several drug candidates that have the potential to modify the underlying cause of the disease.

The report "PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2026", providesoverview of AD: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In depth, this report provides the following -

  • Annualized AD market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild cognitive impairment, mild AD, moderate AD, and severe AD), forecast from 2016 to 2026.
  • Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AD therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AD therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
  • Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report:AB Science, Abbvie, AC Immune, Acadia, Actinogen Medical, Adamas Pharmaceuticals, Allergan, Amgen, Archer Pharmaceuticals

Scope

  • Overview of AD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized AD market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild cognitive impairment, mild AD, moderate AD, and severe AD), forecast from 2016 to 2026.
  • Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AD therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AD therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
  • Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global AD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 10

2 Executive Summary 12

  • 2.1 Alzheimer's Market Forecast to See Double-Digit Sales Growth out to 2026 13
  • 2.2 Allergan, Biogen, and Roche Are Forecast to Lead the AD Market in 2026 14
  • 2.3 Lack of Treatments and Biomarkers Remain As Key Unmet Needs in the AD Market 16
  • 2.4 Opportunities Remain for Disease-Modifying and Symptomatic Drugs Entering the AD Market 16
  • 2.5 Twenty Promising Drugs in Phase II/III or Phase III of Development 17
  • 2.6 What Do Physicians Think? 18

3 Introduction 21

  • 3.1 Catalyst 21
  • 3.2 Related Reports 21

4 Disease Overview 22

  • 4.1 Etiology and Pathophysiology 22
    • 4.1.1 Etiology 23
    • 4.1.2 Pathophysiology 25
  • 4.2 Disease Staging Systems 33
  • 4.3 Symptoms 36
  • 4.4 Prognosis 37
  • 4.5 Quality of Life 38

5 Epidemiology 39

  • 5.1 Disease Background 39
  • 5.2 Risk Factors and Comorbidities 41
  • 5.3 Global and Historical Trends 42
  • 5.4 Forecast Methodology 44
    • 5.4.1 Sources 44
    • 5.4.2 Forecast Assumptions and Methods 47
    • 5.4.3 Total Prevalent Cases of AD 47
    • 5.4.4 Total Prevalent Cases of AD by Severity 50
    • 5.4.5 Total Prevalent Cases of MCI 53
  • 5.5 Epidemiological Forecast for AD (2016-2026) 56
    • 5.5.1 Total Prevalent Cases of AD 56
    • 5.5.2 Age-Specific Total Prevalent Cases of AD 57
    • 5.5.3 Sex-Specific Total Prevalent Cases of AD 58
    • 5.5.4 Total Prevalent Cases of AD by Severity 59
  • 5.6 Epidemiological Forecast for MCI (2016-2026) 60
    • 5.6.1 Total Prevalent Cases of MCI 60
    • 5.6.2 Age-Specific Total Prevalent Cases of MCI 61
    • 5.6.3 Sex-Specific Total Prevalent Cases of MCI 62
  • 5.7 Discussion 62
    • 5.7.1 Epidemiological Forecast Insight 62
    • 5.7.2 Limitations of Analysis 63
    • 5.7.3 Strengths of Analysis 64

6 Disease Management 65

  • 6.1 Diagnosis Overview 65
    • 6.1.1 Probable AD Dementia 68
    • 6.1.2 Preclinical AD 70
    • 6.1.3 MCI 71
  • 6.2 Treatment Overview 73
  • 6.3 Clinical Practice 74
    • 6.3.1 Leading Prescribed Therapies 76
  • 6.4 US 77
  • 6.5 5EU 79
  • 6.6 Japan 82

7 Competitive Assessment 84

  • 7.1 Overview 84
  • 7.2 Product Profiles - Major Brands 85
    • 7.2.1 Aricept (Donepezil Hydrochloride) 85
    • 7.2.2 Exelon (Rivastigmine, Rivastigmine tartrate) 92
    • 7.2.3 Razadyne (Galantamine Hydrobromide) 98
    • 7.2.4 Namenda (Memantine Hydrochloride) 104
    • 7.2.5 Namzaric (Memantine and Donepezil Hydrochlorides) 110
  • 7.3 Other Therapeutic Classes 113

8 Unmet Needs and Opportunity Assessment 115

  • 8.1 Overview 115
  • 8.2 Drugs with Disease-Modifying Mechanisms of Action 116
    • 8.2.1 Unmet Need 116
    • 8.2.2 Gap Analysis 117
    • 8.2.3 Opportunity 118
  • 8.3 Diagnosis in the Prodromal or Presymptomatic Stages 120
    • 8.3.1 Unmet Need 120
    • 8.3.2 Gap Analysis 121
    • 8.3.3 Opportunity 122
  • 8.4 Improved Control of Symptoms 123
    • 8.4.1 Unmet Need 123
    • 8.4.2 Gap Analysis 124
    • 8.4.3 Opportunity 125
  • 8.5 Easier Access to Treatment 126
    • 8.5.1 Unmet Need 126
    • 8.5.2 Gap Analysis 127
    • 8.5.3 Opportunity 128

9 Pipeline Assessment 129

  • 9.1 Overview 129
  • 9.2 Clinical Trial Mapping 130
    • 9.2.1 Clinical Trials by Class 130
  • 9.3 Promising Drugs in Clinical Development 131
    • 9.3.1 Biopharmaceutical Products 134
    • 9.3.2 Gantenerumab 134
    • 9.3.3 Crenezumab 140
    • 9.3.4 Aducanumab 146
    • 9.3.5 Flebogamma + Albutein 151
    • 9.3.6 CAD106 157
    • 9.3.7 Small Molecule 161
    • 9.3.8 Verubecestat 161
    • 9.3.9 Elenbecestat 166
    • 9.3.10 Lanabecestat 171
    • 9.3.11 JNJ-54861911 175
    • 9.3.12 CNP520 179
    • 9.3.13 Azeliragon 182
    • 9.3.14 Pioglitazone 186
    • 9.3.15 Nilvadipine 192
    • 9.3.16 Intepirdine 196
    • 9.3.17 ALZT-OP1 201
    • 9.3.18 TRx-0237 (LMTX) 205
    • 9.3.19 Brexipiprazole 212
    • 9.3.20 Aripiprazole 216
    • 9.3.21 AVP-786 220
    • 9.3.22 ITI-007 224
    • 9.3.23 Other Drugs in Development 228

10 Current and Future Players 231

  • 10.1 Overview 231
  • 10.2 Trends in Corporate Strategy 234
  • 10.3 Company Profiles 235
    • 10.3.1 Allergan 235
    • 10.3.2 Lundbeck 238
    • 10.3.3 Eisai 241
    • 10.3.4 Pfizer 244
    • 10.3.5 Novartis 246
    • 10.3.6 Roche 249
    • 10.3.7 Biogen 251
    • 10.3.8 Eli lilly 253
    • 10.3.9 Merck & Co. 257
    • 10.3.10 AstraZeneca 259
    • 10.3.11 Takeda 261

11 Market Outlook 264

  • 11.1 Global Markets 264
    • 11.1.1 Forecast 264
    • 11.1.2 Drivers and Barriers - Global Issues 268
  • 11.2 US 269
    • 11.2.1 Forecast 269
    • 11.2.2 Key Events 272
    • 11.2.3 Drivers and Barriers 273
  • 11.3 5EU 273
    • 11.3.1 Forecast 273
    • 11.3.2 Key Events 276
    • 11.3.3 Drivers and Barriers 277
  • 11.4 Japan 277
    • 11.4.1 Forecast 277
    • 11.4.2 Key Events 280
    • 11.4.3 Drivers and Barriers 281

12 Appendix 282

  • 12.1 Bibliography 282
  • 12.2 Abbreviations 304
  • 12.3 Methodology 309
    • 12.3.1 Forecasting Methodology 309
    • 12.3.2 Diagnosed Patients 310
    • 12.3.3 Percent Drug-Treated Patients 310
    • 12.3.4 Drugs Included in Each Therapeutic Class 310
    • 12.3.5 Launch and Patent Expiry Dates 311
    • 12.3.6 General Pricing Assumptions 312
    • 12.3.7 Individual Drug Assumptions 313
    • 12.3.8 Generic Erosion 321
    • 12.3.9 Pricing of Pipeline Agents 321
  • 12.4 Primary Research - KOLs Interviewed for This Report 323
    • 12.4.1 KOLs 323
    • 12.4.2 Payers 325
  • 12.5 Primary Research - Prescriber Survey 325
  • 12.6 About the Authors 326
    • 12.6.1 Analyst 326
    • 12.6.2 Therapy Area Director 326
    • 12.6.3 Epidemiologist 326
    • 12.6.4 Managing Epidemiologist 327
    • 12.6.5 Global Director of Therapy Analysis and Epidemiology 327
    • 12.6.6 Global Head and EVP of Healthcare Operations and Strategy 328
  • 12.7 About GlobalData 329
  • 12.8 Contact Us 329
  • 12.9 Disclaimer 330

List of Tables

1.1 List of Tables

  • Table 1: MCI and AD: Key Metrics in the 7MM 12
  • Table 2: Three-Stage Classification of AD 34
  • Table 3: The Seven-Stage Reisberg Scale of AD 35
  • Table 4: Common Symptoms of AD. 37
  • Table 5: DSM-IV Criteria for the Diagnosis of Dementia 40
  • Table 6: NINCDS-ADRDA Criteria for the Diagnosis of AD 41
  • Table 7: Risk Factors and Comorbidities for AD 42
  • Table 8: 7MM, Total Prevalent Cases of AD, Both Sexes, Ages ≥60 Years, Selected Years 2016-2026. 56
  • Table 9: 7MM, Total Prevalent Cases of MCI, Both Sexes, Ages ≥60 Years, Selected Years 2016-2026. 60
  • Table 10: Commonly Used Diagnostic Guidelines for Alzheimer's Disease 66
  • Table 11: Summary of NINCDS-ARDA Diagnostic Criteria for Alzheimer's Disease 68
  • Table 12: Proposed NIA-AA Staging Classification for Preclinical AD 70
  • Table 13: NIA-AA Biomarker Criteria for MCI 72
  • Table 14: Commonly Used Treatment Guidelines for Alzheimer's Disease in the 7MM 74
  • Table 15: Most Prescribed Drugs for AD by Class in the 7MM, 2016 76
  • Table 16: Most Commonly Prescribed Off-Label Drug Classes for AD, by Treatment Line, in the 7MM 76
  • Table 17: Country Profile - US 78
  • Table 18: Region Profile - 5EU, 2017 80
  • Table 19: Country Profile - Japan 83
  • Table 20: Leading Therapies in AD 85
  • Table 21: Product Profile - Aricept 87
  • Table 22: Efficacy Results for Aricept in Mild to Moderate AD 88
  • Table 23: Efficacy Results for Aricept in Moderate to Severe AD 89
  • Table 24: Efficacy Results for Aricept in Severe AD 89
  • Table 25: Aricept SWOT Analysis, 2017 91
  • Table 26: Product Profile - Exelon 93
  • Table 27: Efficacy Results for Exelon Capsule and Oral Solution in AD 94
  • Table 28: Efficacy Results for Exelon Patch in AD 95
  • Table 29: Adverse Events Occurring in at Least 2% of Patients and at a Higher Frequency than Placebo-Treated Patients 96
  • Table 30: Exelon SWOT Analysis, 2017 97
  • Table 31: Product Profile - Razadyne 99
  • Table 32: Efficacy Results for Razadyne in Probable AD 101
  • Table 33: Razadyne SWOT Analysis, 2017 103
  • Table 34: Product Profile - Namenda 105
  • Table 35: Efficacy Results for Namenda and Namenda XR in Alzheimer's Disease 107
  • Table 36: Safety Results for Namenda and Namenda XR in Alzheimer's Disease 108
  • Table 37: Namenda SWOT Analysis, 2017 109
  • Table 38: Product Profile - Namzaric 111
  • Table 39: Namzaric SWOT Analysis, 2017 112
  • Table 40: Summary of Minor Therapeutic Classes, 2017 114
  • Table 41: Comparison of Therapeutic Classes in Development for AD 134
  • Table 42: Product Profile - Gantenerumab 136
  • Table 43: Key Efficacy Results For Gantenerumab 137
  • Table 44: Pipeline Gantenerumab SWOT Analysis, 2017 139
  • Table 45: Ongoing Phase III Trials For Crenezumab, 2017 140
  • Table 46: Product Profile - Crenezumab 142
  • Table 47: Key Efficacy Data for Crenezumab 143
  • Table 48: Pipeline Crenezumab SWOT Analysis, 2017 145
  • Table 49: Product Profile - Aducanumab 148
  • Table 50: Key Efficacy Data for Aducanumab 149
  • Table 51: Key Safety Results For Aducanumab From Phase Ib PRIME Study 149
  • Table 52: Pipeline Aducanumab SWOT Analysis, 2017 151
  • Table 53: Product Profile - Flebogamma + Albutein 154
  • Table 54: Key Efficacy Data for Flebogamma + Albutein 155
  • Table 55: Key Safety Results For Flebogamma + Albutein From AMBAR (Interim Analysis) 155
  • Table 56: Flebogamma + Albutein SWOT Analysis, 2017 157
  • Table 57: Product Profile - CAD106 158
  • Table 58: CAD106 SWOT Analysis, 2017 160
  • Table 59: Product Profile - Verubecestat 163
  • Table 60: Verubecestat SWOT Analysis, 2017 165
  • Table 61: Product Profile - Elenbecestat 167
  • Table 62: Key Efficacy Data for Elenbecestat 169
  • Table 63: Elenbecestat SWOT Analysis, 2017 170
  • Table 64: Product Profile - Lanabecestat 172
  • Table 65: Key Efficacy Data for Lanabecestat 173
  • Table 66: Lanabecestat SWOT Analysis, 2017 174
  • Table 67: Product Profile - JNJ-54861911 176
  • Table 68: Key Efficacy Data for JNJ-54861911 177
  • Table 69: JNJ-54861911 SWOT Analysis, 2017 178
  • Table 70: Product Profile - CNP520 180
  • Table 71: Key Efficacy Data for CNP520 180
  • Table 72: CNP520 SWOT Analysis, 2017 182
  • Table 73: Product Profile - Azeliragon 184
  • Table 74: Azeliragon SWOT Analysis, 2017 186
  • Table 75: Product Profile - Pioglitazone 188
  • Table 76: Key Safety Results For Pioglitazone 190
  • Table 77: Pioglitazone SWOT Analysis, 2017 192
  • Table 78: Product Profile - Nilvadipine 194
  • Table 79: Nilvadipine SWOT Analysis, 2017 196
  • Table 80: Product Profile - Intepirdine 198
  • Table 81: Key Efficacy Results For Intepirdine 199
  • Table 82: Intepirdine SWOT Analysis, 2017 200
  • Table 83: Product Profile - ALZT-OP1 202
  • Table 84: ALZT-OP1 SWOT Analysis, 2017 204
  • Table 86: Product Profile - TRx-0237 207
  • Table 87: Key Efficacy Results for TRx-0237 208
  • Table 88: Key Safety Results For TRx-0237 from the Phase III TRx-237-005 Study 210
  • Table 89: TRx-0237 SWOT Analysis, 2017 211
  • Table 90: Product Profile - Brexipiprazole 213
  • Table 91: Key Efficacy Results For Brexipiprazole 214
  • Table 92: Brexipiprazole SWOT Analysis, 2017 215
  • Table 93: Product Profile - Aripiprazole 217
  • Table 94: Key Efficacy Results For Aripiprazole 218
  • Table 95: Key Safety Results For Aripiprazole 218
  • Table 96: Aripiprazole SWOT Analysis, 2017 220
  • Table 97: Product Profile - AVP-786 221
  • Table 98: AVP-786 SWOT Analysis, 2017 224
  • Table 99: Product Profile - ITI-007 225
  • Table 100: ITI-007 SWOT Analysis, 2017 227
  • Table 101: Drugs in Development for AD and AD-Related Symptoms, 2017 229
  • Table 102: Key Companies in the AD Market in the 7MM, 2017 232
  • Table 103: Allergan's AD Portfolio Assessment, 2017 237
  • Table 104: Lundbeck's AD Portfolio Assessment, 2017 240
  • Table 105: Eisai's AD Portfolio Assessment, 2017 243
  • Table 106: Pfizer's AD Portfolio Assessment, 2017 245
  • Table 107: Novartis's AD Portfolio Assessment, 2017 248
  • Table 108: Roche's AD Portfolio Assessment, 2017 250
  • Table 109: Biogen's AD Portfolio Assessment, 2017 252
  • Table 110: Eli Lilly's AD Portfolio Assessment, 2017 256
  • Table 111: Merck's AD Portfolio Assessment, 2017 258
  • Table 112: AstrasZeneca's AD Portfolio Assessment, 2017 260
  • Table 113: Takeda's AD Portfolio Assessment, 2017 263
  • Table 114: AD Market - Global Drivers and Barriers, 2016-2026 268
  • Table 115: Key Events Impacting Sales for Alzheimer's Disease in the US, 2016-2026 272
  • Table 116: AD Market - Drivers and Barriers in the US, 2016-2026 273
  • Table 117: Key Events Impacting Sales for AD in the 5EU, 2016-2026 276
  • Table 118: AD Market - Drivers and Barriers in the 5EU, 2016-2026 277
  • Table 119: Key Events Impacting Sales for AD in Japan, 2016-2026 280
  • Table 120: AD Market - Global Drivers and Barriers in Japan, 2016-2026 281
  • Table 121: Key Historical and Projected Launch Dates for AD 311

Table 122 : Key Historical and Projected Patent Expiry Dates for AD 312

  • Table 123: High-Prescribing Physicians (non-KOLs) Surveyed, by Country 325

List of Figures

1.2 List of Figures

  • Figure 1: Global Sales Forecast by Country for AD, 2016-2026 14
  • Figure 2: Company Portfolio Gap Analysis in AD, 2016-2026 15
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in AD, 2016-2026 18
  • Figure 4: AD Biomarker Tests by Pathophysiology 31
  • Figure 5: Dynamic Changes in AD Biomarker Over Time 32
  • Figure 6: 7MM, Age-Standardized Total Prevalence of AD (%), Ages ≥60 Years 43
  • Figure 7: 7MM, Age-Standardized Total Prevalence of MCI (%), Ages ≥60 Years 44
  • Figure 8: 7MM, Sources Used and Not Used, Total Prevalent Cases of AD 45
  • Figure 9: 7MM, Sources Used, Total Prevalent Cases of AD by Severity 46
  • Figure 10: 7MM, Sources Used, Total Prevalent Cases of MCI 46
  • Figure 11: 7MM, Age-Specific Total Prevalent Cases of AD, Both Sexes, 2016 57
  • Figure 12: 7MM, Sex-Specific Total Prevalent Cases of AD, Both Sexes, Ages >60 Years, 2016 58
  • Figure 13: 7MM, Total Prevalent Cases of AD by Severity, Both Sexes, Ages ≥60 Years, 2016 59
  • Figure 14: 7MM, Age-Specific Total Prevalent Cases of MCI, Both Sexes, 2016 61
  • Figure 15: 7MM, Sex-Specific Total Prevalent Cases of MCI, Both Sexes, Ages >60 Years, 2016 62
  • Figure 16: Disease Management Timeline For Alzheimer's Disease 75
  • Figure 17: Unmet Need and Opportunity in AD, 2017 116
  • Figure 18: Overview of the Development Pipeline in MCI and AD 129

Figure 19 : Active Phase II and Phase III Clinical Trials in MCI and AD by Drug Class, 2017 130

  • Figure 20: Key Phase II/III and III Trials, Promising Pipeline Agents for MCI and AD, 7MM, 2016-2026 131
  • Figure 21: Key Phase III Trials of Promising Pipeline Agents for AD-Associated Agitation, 7MM, 2016-2026 132
  • Figure 22: Competitive Assessment of the Late-Stage Pipeline Agents for MCI and AD, 2017-2027 133
  • Figure 23: Clinical and Commercial Positioning of Gantenerumab 138
  • Figure 24: Clinical and Commercial Positioning of Crenezumab 144
  • Figure 25: Clinical and Commercial Positioning of Pipeline aducanumab 150
  • Figure 26: Clinical and Commercial Positioning of Pipeline Flebogamma + Albutein 156
  • Figure 27: Clinical and Commercial Positioning of Pipeline CAD106 160
  • Figure 28: Clinical and Commercial Positioning of Verubecestat 165
  • Figure 29: Clinical and Commercial Positioning of Elenbecestat 170
  • Figure 30: Clinical and Commercial Positioning of Lanabecestat 174
  • Figure 31: Clinical and Commercial Positioning of JNJ-54861911 178
  • Figure 32: Clinical and Commercial Positioning of CNP520 181
  • Figure 33: Clinical and Commercial Positioning of Azeliragon 185
  • Figure 34: Clinical and Commercial Positioning of Pioglitazone 191
  • Figure 35: Clinical and Commercial Positioning of Nilvadipine 195
  • Figure 36: Clinical and Commercial Positioning of Intepirdine 200
  • Figure 37: Clinical and Commercial Positioning of ALZT-OP1 204
  • Figure 38: Clinical and Commercial Positioning of TRx-0237 211
  • Figure 39: Clinical and Commercial Positioning of Brexipiprazole 215
  • Figure 40: Clinical and Commercial Positioning of Aripiprazole 219
  • Figure 41: Clinical and Commercial Positioning of AVP-786 223
  • Figure 42: Clinical and Commercial Positioning of ITI-007 227
  • Figure 43: Global Sales of AD Products, by Company, 2016 and 2026 233
  • Figure 44: Company Portfolio Gap Analysis in AD, 2016-2026 234
  • Figure 45: Allergan SWOT Analysis, 2017 238
  • Figure 46: Lundbeck SWOT Analysis, 2017 241
  • Figure 47: Eisai SWOT Analysis, 2017 243
  • Figure 48: Pfizer SWOT Analysis, 2017 246
  • Figure 49: Novartis SWOT Analysis, 2017 248
  • Figure 50: Roche SWOT Analysis, 2017 250
  • Figure 51: Biogen SWOT Analysis, 2017 253
  • Figure 52: Eli Lilly SWOT Analysis, 2017 257
  • Figure 53: Merck SWOT Analysis, 2017 259

Figure 54: AstraZeneca SWOT Analysis 261

  • Figure 55: Takeda SWOT Analysis, 2017 263
  • Figure 56: 7MM Sales Forecast by Country for AD, 2016 and 2026 267
  • Figure 57: Sales Forecast by Class for AD in the US in 2016 and 2026 271
  • Figure 58: Sales Forecast by Class for AD in the 5EU, 2016 and 2026 275
  • Figure 59: Sales Forecast by Class for AD in Japan in 2016 and 2026 279
Back to Top